Phase II studies demonstrated that anakinra administered within 6 h of stroke onset was safe and led to reductions in circulating neutrophils, CRP, and IL-6 levels, suggesting systemic anti-inflammatory effects. This evidence concerns the gene IL6 and stroke disorder.